Search research articles
Contact Us
Filters
Showing results (1-10 of 24) with videos related to
Page
of 3
Sort By:
The British Journal of Radiology
|
March 9, 2016
A comparison of two post-processing analysis methods to quantify cerebral metabolites measured via proton magnetic resonance spectroscopy in HIV disease
Joseph Scott, Jonathan Underwood, Lucy J Garvey, et al.
BMJ Case Reports
|
February 14, 2019
Disseminated CMV infection and HLH in a patient with well-controlled HIV and ulcerative colitis
Beatrice Clare Cockbain, Borja Mora Peris, Aula Abbara, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
September 14, 2017
Cognitive Impairment in a Clinical Setting
Francesca Ferretti, Borja Mora-Peris, Jonathan Underwood, et al.
AIDS Research and Therapy
|
April 16, 2016
Evolution of changes in cognitive function after the initiation of antiretroviral therapy
Borja Mora-Peris, Elizabeth Stevens, Francesca Ferretti, et al.
The Journal of Antimicrobial Chemotherapy
|
October 17, 2015
HIV-1 CNS in vitro infectivity models based on clinical CSF samples
Borja Mora-Peris, Alan Winston, Lucy Garvey, et al.
AIDS (London, England)
|
April 25, 2015
Apparent spontaneous clearance of chronic hepatitis C virus infection in a HIV co-infected patient with decompensated cirrhosis: a case report
Borja Mora-Peris, Robert D Goldin, David Muir, et al.
The Journal of Antimicrobial Chemotherapy
|
February 20, 2015
A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers
Borja Mora-Peris, Laura Else, David Goldmeier, et al.
The Journal of Antimicrobial Chemotherapy
|
February 1, 2013
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects
Borja Mora-Peris, Adam Croucher, Laura J Else, et al.
HIV Clinical Trials
|
March 18, 2015
The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age
Jaime H Vera, Akil Jackson, Laura Dickinson, et al.
HIV Medicine
|
May 22, 2025
HIV seroconversions and genotypic viral resistance profiles in the PrEP impact trial
Andrea Cartier, Ana Milinkovic, Lisa Goodall, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 24) with videos related to
Sort By:
Page
of 3
The British Journal of Radiology
|
March 9, 2016
A comparison of two post-processing analysis methods to quantify cerebral metabolites measured via proton magnetic resonance spectroscopy in HIV disease
Joseph Scott, Jonathan Underwood, Lucy J Garvey, et al.
BMJ Case Reports
|
February 14, 2019
Disseminated CMV infection and HLH in a patient with well-controlled HIV and ulcerative colitis
Beatrice Clare Cockbain, Borja Mora Peris, Aula Abbara, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
September 14, 2017
Cognitive Impairment in a Clinical Setting
Francesca Ferretti, Borja Mora-Peris, Jonathan Underwood, et al.
AIDS Research and Therapy
|
April 16, 2016
Evolution of changes in cognitive function after the initiation of antiretroviral therapy
Borja Mora-Peris, Elizabeth Stevens, Francesca Ferretti, et al.
The Journal of Antimicrobial Chemotherapy
|
October 17, 2015
HIV-1 CNS in vitro infectivity models based on clinical CSF samples
Borja Mora-Peris, Alan Winston, Lucy Garvey, et al.
AIDS (London, England)
|
April 25, 2015
Apparent spontaneous clearance of chronic hepatitis C virus infection in a HIV co-infected patient with decompensated cirrhosis: a case report
Borja Mora-Peris, Robert D Goldin, David Muir, et al.
The Journal of Antimicrobial Chemotherapy
|
February 20, 2015
A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers
Borja Mora-Peris, Laura Else, David Goldmeier, et al.
The Journal of Antimicrobial Chemotherapy
|
February 1, 2013
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects
Borja Mora-Peris, Adam Croucher, Laura J Else, et al.
HIV Clinical Trials
|
March 18, 2015
The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age
Jaime H Vera, Akil Jackson, Laura Dickinson, et al.
HIV Medicine
|
May 22, 2025
HIV seroconversions and genotypic viral resistance profiles in the PrEP impact trial
Andrea Cartier, Ana Milinkovic, Lisa Goodall, et al.
Page
of 3